Vivos Also Announces Improved Pricing Agreement With SleepImage
Dentists and Patients Report Exceptional User Experience with SleepImage Home Sleep Test
Vivos Therapeutics, Inc. (“Vivos” or “the Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, today announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST).
In particular, for the three-months ended December 31, 2021, versus the three-months ended December 31, 2020, Vivos reported:
an 18 times increase in the total number of HSTs given across the network of Vivos trained dentists (known as Vivos Integrated Practices or VIPs);
a 5.7 times increase in the number of VIPs administering HSTs; and
a 3 times increase in the average number of HSTs being administered per VIP.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.